QUASIR RAZA: Open Payments
NPI 1497846943 · ROANOKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,131 in 60 payments from 18 companies in 2025. Trend: 2023 $1,545 · 2024 $1,234 · 2025 $1,131
Food & beverage: $1,131
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 16 | $174 |
| UCB, Inc. | 5 | $156 |
| GlaxoSmithKline, LLC. | 8 | $149 |
| PFIZER INC. | 5 | $99 |
| ARGENX US, INC. | 3 | $79 |
| Novo Nordisk Inc | 3 | $69 |
| Abbott Laboratories | 3 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $51 |
| ABBVIE INC. | 3 | $49 |
| Lilly USA, LLC | 2 | $39 |
Products named: TRELEGY ELLIPTA, OTEZLA, Rystiggo, VYVGART HYTRULO, PREVNAR 20, Zilbrysq, FREESTYLE LIBRE 3, CAPLYTA.
Industry payments across VA — which companies pay providers there.
